AmMax has established a highly differentiated oncology pipeline addressing large commercial opportunities. At the core of the portfolio is AMB-101, a novel antibody-drug conjugate (ADC) enabled by a proprietary next generation topoisomerase I inhibitor-based linker-payload that has demonstrated a broadened therapeutic index and will enter the clinic in the second half of 2023. AMB-101 targets a tumor associated antigen overexpressed across a broad range of solid tumors and has shown robust efficacy in multiple preclinical models.

​

The Company’s portfolio is further strengthened by AMB-05X, a clinical phase mAb targeting CSF1R for the treatment of tenosynovial giant cell tumor (TGCT) wherein an overexpression of CSF1 drives the pathogenesis. With positive clinical proof of concept data, AMB-05X is currently in a Phase 2b trial as the only local pharmacological therapy for this debilitating local tumor. It is uniquely positioned to reach a large and untapped segment of the TGCT patients.

​

AmMax continues to expand its reach into oncology via active partnering and licensing.